CSANZ-Boehringer Ingelheim Cardiovascular Research Innovation Grants

The CSANZ-Boehringer Ingelheim and Eli Lilly research innovation grants have been made possible through unrestricted funding from Boehringer Ingelheim and Eli Lilly.  The grants aim to stimulate and support innovative and ground-breaking research in cardiovascular and cardio-metabolic medicine by early to mid-career researchers.

In 2019, there will be two grants awarded, each to the value of AUD50,000:

1. CSANZ-Boehringer Ingelheim Cardiovascular Research Innovation Grant

2. CSANZ-Boehringer Ingelheim and Eli Lilly Diabetes Alliance Cardio-metabolic Research Innovation Grant

SCOPE OF THE GRANTS

CSANZ-Boehringer Ingelheim Cardiovascular Research Innovation Grant

Both interventional and observational studies within the following fields will be considered:

  • Thromboembolic Disease (general)
  • Atrial Fibrillation
  • Stroke
  • Deep Vein Thrombosis / Pulmonary Embolism
  • Percutaneous Coronary Intervention
  • Coronary Artery Disease and / or Peripheral Artery Disease

CSANZ-Boehringer Ingelheim and Eli Lilly Cardio-Metabolic Research Innovation Grant

Both interventional and observational studies within the following fields will be considered:

  • Type 2 Diabetes
  • Cardio-Metabolic Syndrome and Heart Failure
  • Cardiovascular Complications of Diabetic Kidney Disease

Applicants must be:

  • a member of the Cardiac Society of Australia and New Zealand (or have an application for membership pending by the grant closing date)
  • six years or less post-award of PhD or a postgraduate qualification
  • domiciled in Australia or New Zealand
  • affiliated with an academic/scientific institution or national health care system

Click here for further information.

Click this link to download an application form.

APPLICATIONS CLOSE ON 3 MAY, 2019.